Minerva Neurosciences Inc. (NASDAQ:NERV) shares were up 3.5% during trading on Tuesday . The stock traded as high as $14.40 and last traded at $14.33, with a volume of 126,588 shares. The stock had previously closed at $13.84.

Several research analysts recently commented on NERV shares. JMP Securities raised their target price on Minerva Neurosciences from $10.00 to $17.00 in a research report on Thursday, May 26th. Jefferies Group reaffirmed a “buy” rating and issued a $17.00 target price (up from $10.00) on shares of Minerva Neurosciences in a research report on Friday, May 27th. Finally, Zacks Investment Research cut Minerva Neurosciences from a “buy” rating to a “sell” rating in a research report on Wednesday, June 1st.

The stock’s 50-day moving average price is $12.37 and its 200 day moving average price is $9.18. The company’s market capitalization is $500.15 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/minerva-neurosciences-inc-nerv-trading-up-3-5.html

Minerva Neurosciences (NASDAQ:NERV) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.12. During the same period last year, the business earned ($0.27) EPS. Equities analysts anticipate that Minerva Neurosciences Inc. will post ($0.90) EPS for the current year.

In other Minerva Neurosciences news, major shareholder Venture Associates L. Index III sold 1,000,000 shares of the company’s stock in a transaction on Wednesday, August 10th. The stock was sold at an average price of $10.00, for a total value of $10,000,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 28.10% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in NERV. Nationwide Fund Advisors acquired a new stake in shares of Minerva Neurosciences during the second quarter valued at $106,000. Parametric Portfolio Associates LLC acquired a new stake in shares of Minerva Neurosciences during the second quarter valued at $107,000. Highbridge Capital Management LLC acquired a new stake in shares of Minerva Neurosciences during the second quarter valued at $138,000. Sterling Capital Management LLC increased its stake in shares of Minerva Neurosciences by 36.1% in the second quarter. Sterling Capital Management LLC now owns 13,613 shares of the biopharmaceutical company’s stock valued at $139,000 after buying an additional 3,613 shares in the last quarter. Finally, Bank of Montreal Can acquired a new stake in shares of Minerva Neurosciences during the second quarter valued at $156,000. Hedge funds and other institutional investors own 63.19% of the company’s stock.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio include MIN-101 for the treatment of schizophrenia; MIN-117 for the treatment of major depressive disorder (MDD); MIN-202 (also known as JNJ-42847922) for the treatment of insomnia disorder and adjunctive MDD, and MIN-301 for the treatment of Parkinson’s disease.

5 Day Chart for NASDAQ:NERV

Receive News & Ratings for Minerva Neurosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.